BR55 clinical trials
Also written BR55.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses BR55 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BR55
- 5
Studies by the year they started
5 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2014 | 1 |
| 2018 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses BR55 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- BR55 in Characterization of Ovarian LesionsTerminatedPhase 2Bracco Diagnostics, IncNCT03493464Written as BR55
- Transabdominal Ultrasound With BR55 for Characterization of Pancreatic LesionsTerminatedPhase 2Bracco Diagnostics, IncNCT03486327Written as BR55
- Optimal Timing of BR55 CEUS of the OvariesTerminatedPhase 2Bracco Diagnostics, IncNCT04248153Written as BR55
- BR55 in Prostate Cancer: an Exploratory Clinical TrialCompletedEarly Phase 1Bracco Diagnostics, IncNCT01253213Written as BR55
- A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate CancerCompletedPhase 1/2Bracco Diagnostics, IncNCT02142608Written as BR55